XML 29 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Narrative) (Detail) (USD $)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Dec. 31, 2011
Jun. 30, 2012
Dec. 31, 2011
Jun. 30, 2011
Jun. 30, 2010
Schedule Of Significant Accounting Policies [Line Items]                          
Accumulated other comprehensive income attributable to foreign currency translation $ 950,000       $ 1,400,000         $ 950,000   $ 1,400,000  
Interest-bearing cash equivalent 4,300,000                 4,300,000      
Revenues 699,000 538,000 630,000 [1] 1,659,000 [2] 3,715,000 [3] 360,000 414,000 476,000   3,526,000 [1],[2]   4,965,000 [3] 23,053,000
Estimated useful lives of assets                   3 years      
Impairment of intangible assets     14,800,000           (14,830,000) 14,830,000 14,800,000    
Collaborative research and development revenues                       3,300,000  
Tax benefit to be recognized for any tax position                   50.00%      
Durasert And BioSilicon
                          
Schedule Of Significant Accounting Policies [Line Items]                          
Finite life intangible assets amortization period                   12 years      
Pfizer | Customer Concentrations of Risk
                          
Schedule Of Significant Accounting Policies [Line Items]                          
Revenues                   754,000.0   3.3  
Percentage of total revenues                   21.00%   67.00%  
Bausch and Lomb | Customer Concentrations of Risk
                          
Schedule Of Significant Accounting Policies [Line Items]                          
Revenues                   1.4   1.4  
Percentage of total revenues                   41.00%   27.00%  
Alimera | Customer Concentrations of Risk
                          
Schedule Of Significant Accounting Policies [Line Items]                          
Revenues                         $ 22.3
Percentage of total revenues                         97.00%
[1] Results for the second quarter of fiscal 2012 included a $14.8 million impairment write-down of finite-lived intangible assets (see Note 4).
[2] Results for the first quarter of fiscal 2012 included $1.1 million of revenue related to the termination of a field-of-use license by Intrinsiq (see Note 3)
[3] Results for the fourth quarter of fiscal 2011 included $3.3 million of revenue related to a material modification of the Pfizer collaborative research and license agreement in June 2011 (see Note 3).